Gene Signatures in Colorectal Cancer

2011 ◽  
pp. 115-136 ◽  
Author(s):  
Alessandro Lugli ◽  
Inti Zlobec
Keyword(s):  
Colorectal Cancer ◽  
Gene Signatures

scholarly journals Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer

2017 ◽  
Vol 13 (4) ◽  
pp. 2089-2096 ◽  
Author(s):  
Xinrong Sun ◽  
Xiang Wang ◽  
Wenming Feng ◽  
Huihui Guo ◽  
Chengwu Tang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Poor Prognosis ◽  
Gene Signatures

scholarly journals Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells

PLoS Genetics ◽  
2010 ◽  
Vol 6 (12) ◽  
pp. e1001231 ◽  
Author(s):  
Karsten Jürchott ◽  
Ralf-Jürgen Kuban ◽  
Till Krech ◽  
Nils Blüthgen ◽  
Ulrike Stein ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Binding Protein ◽  
Erk Pathway ◽  
Gene Signatures ◽  
Colorectal Cancer Cells

MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3529-3529 ◽  
Author(s):  
Kanwal Pratap Singh Raghav ◽  
Hesham M. Amin ◽  
Wenting Wang ◽  
Ganiraju C. Manyam ◽  
Bradley Broom ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Overall Survival ◽  
Protein Expression ◽  
Protein Gene ◽  
Epithelial Mesenchymal Transition ◽  
Mesenchymal Transition ◽  
Gene Signatures ◽  
Protein Levels ◽  
Emt Markers

3529 Background: Epithelial-mesenchymal transition (EMT) has been identified as a dominant molecular subtype of colorectal cancer (CRC). This EMT phenotype as recognized by complex gene signatures is prognostic and associated with chemoresistance, but a biomarker for EMT suitable for clinical utilization has not yet been validated. The purpose of this study was to compare MET protein expression with protein/gene expression of EMT markers and to evaluate its impact on overall survival (OS). Methods: We performed an exploratory analysis of 139 untreated primary CRC samples using data from The Cancer Genome Atlas. Protein and gene expressions were measured using reverse-phase protein array (RPPA) and RNA-sequencing, respectively. MET high/overexpressed group was defined by protein level in the highest quartile. Mann-Whitney U-test and Spearman rank correlation was used to determine association between MET protein expression and protein/gene expression of EMT markers and EMT gene signature scores. Regression tree method and Kaplan-Meier estimates were used to assess overall survival (OS). Results: The MET protein distribution is right skewed, demonstrating a unique population of MET high expressing tumors (P < 0.01). Colon tumors had higher MET protein levels compared to rectal tumors (P < 0.01). MET overexpression was associated with decreased OS (HR 2.92; 95% CI: 1.45 - 5.92). MET protein expression correlated strongly with protein expressions of SLUG (transcription factor for EMT) (r = 0.6) and ERCC1 (a marker for oxaliplatin chemo-resistance) (r = 0.6) (P < 0.01). Higher MET protein levels were associated with higher gene expression of 28 EMT markers including AXL, VIM, ZEB1, ZEB2, FGF1, TGFB1I1 and MMP11 (P < 0.05). Higher MET protein levels were also associated with higher gene scores derived from three published EMT gene signatures (P < 0.05). MET protein expression did not correlate with MET gene expression (r = 0.16). Conclusions: Increased MET protein expression strongly correlates with a molecular EMT phenotype and poor survival in patients with CRC. MET protein expression may be used as a surrogate biomarker to represent and select for this unique molecular subset of CRC driven by EMT biology.

scholarly journals Gene signatures of drug resistance predict patient survival in colorectal cancer

2014 ◽  
Vol 15 (2) ◽  
pp. 135-143 ◽  
Author(s):  
Y Zheng ◽  
J Zhou ◽  
Y Tong
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Patient Survival ◽  
Gene Signatures

scholarly journals KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 3206-3225 ◽  
Author(s):  
Qing Wen ◽  
Philip D. Dunne ◽  
Paul G. O’Reilly ◽  
Gerald Li ◽  
Anthony J. Bjourson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Cancer Gene ◽  
Angiotensin Ii Receptor ◽  
Gene Signatures ◽  
Receptor Blockers

scholarly journals Cliques for the identification of gene signatures for colorectal cancer across population

2012 ◽  
Vol 6 (Suppl 3) ◽  
pp. S17 ◽  
Author(s):  
Meeta P Pradhan ◽  
Kshithija Nagulapalli ◽  
Mathew J Palakal
Keyword(s):  
Colorectal Cancer ◽  
Gene Signatures
Sign in / Sign up

Export Citation Format

Share Document